Table 1 Clinical studies on the role of corticosteroids in severe community-acquired pneumonia
From: The role of corticosteroids in severe community-acquired pneumonia: a systematic review
Reference | Study design | Sample size, number | Patient selection | Corticosteroids (drug/regimen) | Primary endpoints | Level of evidence and recommendation |
|---|---|---|---|---|---|---|
Marik, et al. [21] | Single-center RCT | 30 | Severe CAP | Hydrocortisone 10 mg/kg versus placebo 30 minutes before antibiotics | Mortality, clinical course, and serum TNF-α levels | Weak recommendation, moderate-quality evidence |
Confalonieri, et al. [6] | Multicenter RCT | 46 | Severe CAP | Hydrocortisone 200 mg + hydrocortisone 10 mg/hour for 7 days versus placebo | Mortality, clinical course, and systemic inflammation | Strong recommendation, moderate-quality evidence |
Mikami, et al. [20] | Open-label RCT | 31 | Moderate and severe CAP | Prednisolone 40 mg qd for 3 days versus placebo | Mortality and clinical course | Weak recommendation, low-quality evidence |
Garcia-Vidal, et al. [19] | Retrospective cohort study | 308 | Severe CAP | Methylprednisolone 14.5 mg (or equivalent) qd for 11.4 days | Mortality | Strong recommendation, low-quality evidence |